Elan says another MS patient on Tysabri drug has brain infection; Major shareholder calls for ouster of CEO Kelly Martin
Dec 16th, 2008 | By Finfacts Ireland Business & Finance Portal | Category: News worldwide
Elan and its US partner Biogen announced on Monday that another patient on the multiple sclerosis (MS) drug Tysabri has been diagnosed with a brain infection. In related news, a major shareholder has publicly called for the ouster of Elan's CEO Kelly Martin.